Natera, Inc. $NTRA Shares Bought by Inceptionr LLC

Inceptionr LLC lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 55.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,526 shares of the medical research company’s stock after buying an additional 2,337 shares during the period. Inceptionr LLC’s holdings in Natera were worth $1,305,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NTRA. JPMorgan Chase & Co. lifted its stake in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. Wellington Management Group LLP boosted its stake in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. State Street Corp increased its stake in Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares in the last quarter. Coatue Management LLC boosted its position in Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Natera by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock valued at $596,078,000 after buying an additional 11,689 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NTRA opened at $264.69 on Friday. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The business has a 50-day moving average of $239.24 and a two-hundred day moving average of $221.33. The stock has a market capitalization of $37.91 billion, a price-to-earnings ratio of -162.39 and a beta of 1.51.

Insider Buying and Selling

In other news, Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the sale, the director directly owned 4,250 shares of the company’s stock, valued at $1,062,500. The trade was a 79.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,405 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the sale, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. The trade was a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 178,872 shares of company stock worth $39,627,696 over the last 90 days. Company insiders own 5.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NTRA. JPMorgan Chase & Co. raised their target price on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Robert W. Baird set a $265.00 target price on Natera in a report on Friday, May 8th. Piper Sandler reissued an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Finally, Barclays dropped their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average target price of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.